Second-generation antihistamines are the proven starting point for treating hives, and they work for most people with both acute and chronic forms. But a sizable minority of people with chronic hives don’t get adequate relief from a standard dose, and the treatment landscape stretches well beyond what you can pick up at the pharmacy. From prescription-strength dose increases to injectable biologics and newly approved drugs, effective options exist at every level of severity. The trick is knowing what to try, in what order, and when it’s time to escalate.
What Drives Hives in the First Place
Hives, known medically as urticaria, are raised, itchy welts that appear when mast cells in the upper layer of the skin release histamine and other inflammatory chemicals. These mast cells sit in exactly the right spot to cause swelling and trigger nearby sensory nerves, which is why hives itch so intensely and seem to appear out of nowhere.1PubMed. The role and relevance of mast cells in urticaria When hives last fewer than six weeks, they’re classified as acute. When they persist beyond six weeks, they become chronic urticaria, and that’s where treatment gets more complicated.
Acute hives often have an identifiable trigger: a food, a medication, an insect sting, or a viral infection. Chronic spontaneous urticaria (CSU) is a different animal. In roughly half of CSU patients, the immune system appears to be driving the problem through autoantibodies that activate mast cells without any external allergen.2PubMed Central. Autoimmune Theories of Chronic Spontaneous Urticaria Some of these patients also have an increased rate of autoimmune thyroid disease.3Journal of Allergy and Clinical Immunology. Assessment of autoimmunity in patients with chronic urticaria Understanding this autoimmune dimension matters because it explains why antihistamines alone sometimes aren’t enough and why treatments targeting deeper parts of the immune response have become so important.
Antihistamines and the Updosing Strategy
The universal first step for any type of hives is a second-generation (non-sedating) antihistamine. Drugs like cetirizine, loratadine, fexofenadine, and levocetirizine block the histamine receptors responsible for itching, redness, and swelling. For a single acute episode, an over-the-counter dose often does the job. The situation changes with chronic hives. If a standard once-daily dose doesn’t bring your symptoms under control within two to four weeks, current guidelines recommend increasing that same antihistamine up to four times the standard dose before moving on to other therapies.
That fourfold increase sounds dramatic, but the safety data is reassuring. A review of the evidence found that bilastine, fexofenadine, levocetirizine, and cetirizine all earned the strongest recommendation for updosing, with no dose-dependent rise in side effects apart from some additional drowsiness with cetirizine.4PubMed Central. Efficacy and Safety of Up-dosed Second-generation Antihistamines in Uncontrolled Chronic Spontaneous Urticaria: A Review No heart-related complications were reported at higher-than-licensed doses across any of the studied medications. In one trial, increasing levocetirizine or desloratadine up to four times the standard dose improved symptoms in about three-quarters of patients with difficult-to-treat chronic hives.5PubMed. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria
One important practical detail: updosing a single antihistamine generally works better than combining several different ones at their standard doses. Research directly comparing these approaches found that taking one antihistamine at four times the standard dose achieved better complete control of hives than mixing four different antihistamines.6PubMed Central. Efficacy of Second-Line Treatments in Chronic Urticaria Refractory to Standard Dose Antihistamines First-generation antihistamines like diphenhydramine (Benadryl) are sometimes used for acute flares but aren’t recommended as routine chronic therapy because of their sedating effects and shorter duration of action.
Add-On Medications When Antihistamines Fall Short
For the subset of people whose hives don’t respond even to high-dose antihistamines, several add-on medications can help bridge the gap. One commonly tried option is montelukast, a leukotriene receptor antagonist originally developed for asthma. It blocks a different branch of the inflammatory cascade than antihistamines do. Studies have found that adding montelukast to antihistamine therapy provides at least some benefit in roughly half of patients with chronic hives that resist antihistamines alone.7PubMed. Efficacy of montelukast as added therapy in patients with chronic idiopathic urticaria When combined with both an H1 antihistamine and an H2 blocker (like famotidine), leukotriene antagonists have shown promise for refractory cases that didn’t respond to either drug class alone.8PubMed. Efficacy of leukotriene receptor antagonist with anti-H1 receptor antagonist plus anti-H2 receptor antagonist for treatment of refractory chronic idiopathic urticaria
These add-ons are modest in their effect size compared to the treatments discussed below, but they carry very few risks and are inexpensive. For someone whose hives are partly but not fully controlled on high-dose antihistamines, layering in montelukast or an H2 blocker is a reasonable intermediate step before moving to more potent therapies.
Omalizumab for Antihistamine-Resistant Hives
Omalizumab (brand name Xolair) was the first biologic therapy approved specifically for chronic spontaneous urticaria that doesn’t respond to antihistamines, and it remains one of the most effective options available. It works by binding to immunoglobulin E (IgE), the antibody involved in allergic reactions, reducing the activation of mast cells. You receive it as an injection, typically every four weeks.
The clinical evidence is strong. In a large randomized trial published in the New England Journal of Medicine, patients receiving 300 mg of omalizumab saw their weekly itch scores drop by about 10 points from baseline, compared to roughly 5 points for placebo, a clinically meaningful difference.9PubMed. Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria A meta-analysis pooling multiple randomized trials confirmed that omalizumab significantly reduced itch scores, hive counts, and quality-of-life impairment, with no increase in overall side effects compared to placebo.10American Journal of Therapeutics. Efficacy and Safety of Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials The drug is generally well tolerated, though symptoms tend to return after it’s stopped, meaning some patients need ongoing treatment.11PubMed Central. Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
Sleep disruption is one of the most underappreciated burdens of chronic hives, and omalizumab addresses that too. Patients receiving the 300 mg dose showed the most improvement in sleep quality, with the biggest gains occurring in the first four weeks of treatment. Sleep problems worsened again after the drug was discontinued, reinforcing that ongoing therapy may be needed for people with severe disease.
Short Courses of Corticosteroids for Acute Flares
Oral corticosteroids like prednisone are powerful anti-inflammatory drugs, and they can dramatically speed recovery during a bad flare. In one trial of acute hives, patients who received a short course of prednisone alongside an antihistamine had itch scores near zero by day five, while the placebo group was still significantly symptomatic.12PubMed. Outpatient management of acute urticaria: the role of prednisone A systematic review found that for patients whose hives have a low to moderate chance of resolving with antihistamines alone, adding corticosteroids improves outcomes by about 14 to 15 percentage points, though it also roughly doubles the risk of side effects during the treatment course.13PubMed. Efficacy and Safety of Systemic Corticosteroids for Urticaria: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
The critical caveat is that steroids are for short-term rescue, not long-term management. Repeated or prolonged courses carry serious risks: weight gain, bone thinning, blood sugar spikes, immune suppression, and more. If you find yourself reaching for prednisone month after month, that’s a strong signal to pursue one of the targeted therapies described in this article rather than cycling through steroid bursts.
Cyclosporine for Severe, Refractory Cases
Cyclosporine is an immunosuppressant that works by dampening the overactive immune signals driving hives. It’s reserved for people who have failed antihistamines and other therapies, and it’s used off-label for this purpose. A meta-analysis found that response rates climbed steadily with treatment duration: about 54% of patients responded after four weeks, 66% after eight weeks, and 73% after twelve weeks.14PubMed. Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis and Systematic Review A randomized placebo-controlled trial confirmed that 16 weeks of cyclosporine produced significantly fewer treatment failures than placebo, though two patients had to stop because of high blood pressure.15PubMed. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial
Side effects are dose-dependent. At very low doses, only about 6% of patients experienced any adverse event, but that number jumped to 57% at moderate doses.14PubMed. Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis and Systematic Review Blood pressure and kidney function need regular monitoring. Because of this side-effect profile, cyclosporine is typically used as a bridge therapy, meant to suppress the disease for months while hoping it enters natural remission, rather than as an indefinite treatment.
Newer Drugs Changing the Landscape
The treatment pipeline for chronic hives has exploded in recent years. In 2025, two new drugs were approved for antihistamine-refractory CSU within months of each other: dupilumab (an injectable biologic that blocks a receptor involved in type-2 inflammation) and remibrutinib (an oral pill that inhibits Bruton’s tyrosine kinase, a signaling molecule inside mast cells).16PubMed Central. Emerging and Newly Approved Therapies for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Narrative Review These represent fundamentally different approaches to the problem. Dupilumab attacks the upstream inflammatory signals that activate mast cells, while remibrutinib shuts down mast cell activity from the inside.
In phase 3 trials at 24 weeks, complete response rates ran between 30 and 32% for dupilumab and 28 to 32% for remibrutinib. A third agent, barzolvolimab, an anti-KIT antibody that directly depletes mast cells, achieved complete response in 38 to 51% of patients in a phase 2 trial at 12 weeks.17PubMed Central. Update on the Treatment of Chronic Spontaneous Urticaria Head-to-head comparisons between BTK inhibitors and anti-cytokine biologics in phase 2 data suggest remibrutinib may have the edge in raw symptom reduction, though dupilumab has an established long-term safety profile from years of use in eczema and asthma.18PubMed Central. Comparing novel treatments in chronic spontaneous urticaria: A critical appraisal of Bruton’s tyrosine kinase inhibitors versus anti‐cytokine biologics in clinical trials
The practical significance for patients is enormous. Remibrutinib is taken as a pill rather than an injection, which removes a major barrier for people uncomfortable with needles or regular clinic visits. And having multiple drugs with different mechanisms means that if one doesn’t work, a genuinely different approach is available rather than just another variation on the same theme.
NSAIDs and Other Medications That Make Hives Worse
One of the most overlooked factors in stubborn hives is medication-triggered worsening. Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and aspirin can flare chronic urticaria in up to 30% of people who already have the condition. This reaction isn’t a true drug allergy; it happens because NSAIDs shift the balance of inflammatory chemicals in the skin in a way that tips already-irritable mast cells over the edge. If you have chronic hives and take NSAIDs regularly for pain, switching to acetaminophen (Tylenol) or discussing alternatives with your doctor is one of the simplest changes that can make a real difference.
Dietary Approaches
Diet is a topic that generates a lot of interest among hives sufferers, and the evidence, while not overwhelming, is worth knowing about. Certain foods are naturally high in histamine or trigger histamine release: aged cheeses, fermented foods, cured meats, alcohol (especially wine), and some shellfish. A study testing a histamine-free diet in adults with chronic spontaneous urticaria found significant reductions in both symptom scores and blood histamine levels after the dietary change.19PubMed Central. A Histamine-Free Diet Is Helpful for Treatment of Adult Patients with Chronic Spontaneous Urticaria
A separate approach targets so-called pseudoallergens: food additives, preservatives, and natural flavor compounds that can activate mast cells without involving the classic allergy pathway. In a prospective trial of 140 patients, about one in three benefited from a pseudoallergen-free diet, with 14% showing strong improvement and another 14% showing partial improvement.20PubMed. Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: a prospective trial These diets are restrictive and hard to maintain, so they’re best attempted as a structured elimination trial over several weeks rather than as a permanent lifestyle change. If symptoms don’t improve within that window, the diet probably isn’t the answer for you.
The Stress and Hives Connection
People with chronic hives often report that stress makes their symptoms worse, and this isn’t just perception. The skin and the nervous system are deeply connected, and psychological stress can activate the same neuroimmune pathways that trigger mast cell degranulation. A systematic review found that many patients with chronic spontaneous urticaria report a significant life stressor preceding the onset of their hives, and the prevalence of anxiety and depression among these patients is substantially higher than in the general population.21PubMed. Psychological Stress and Chronic Urticaria: A Neuro-immuno-cutaneous Crosstalk. A Systematic Review of the Existing Evidence Research in adolescents confirmed this bidirectional relationship: students with CSU had higher levels of itching, sleep disturbance, anxiety, and depression than their peers.22PubMed Central. Association of Chronic Spontaneous Urticaria With Anxiety and Depression in Adolescents: A Mediation Analysis
This doesn’t mean stress “causes” hives or that you can think your way out of them. But it does mean that stress reduction techniques, treatment for underlying anxiety or depression, and adequate sleep can function as meaningful complements to drug therapy. Ignoring the psychological component while escalating medications is a common mistake.
Hives During Pregnancy
Pregnancy presents a unique challenge because the range of safe medications narrows. International guidelines recommend following the same stepwise approach used in the general population: start with a standard dose of a second-generation antihistamine, increase up to fourfold if needed, and add omalizumab if antihistamines aren’t enough.23PubMed Central. Urticaria in Pregnancy and Lactation That said, the guidelines also acknowledge a lack of strong safety data for most hives treatments during pregnancy. Among the antihistamines, cetirizine and loratadine have the longest track record of use in pregnant women. Omalizumab registry data so far has not raised major safety signals, but the evidence base is still smaller than for non-pregnant adults. Any treatment decisions during pregnancy need to be made in close consultation with both an allergist and an obstetrician.
Physical Triggers and Inducible Hives
Not all chronic hives appear out of the blue. Inducible urticarias are triggered by specific physical stimuli: cold air or water, pressure on the skin, vibration, heat, exercise, or even just scratching (a subtype called dermatographism, where you can literally write on your skin with a fingernail and watch the letters swell up). These forms are treated with the same second-generation antihistamines used for spontaneous hives, and those antihistamines are the only approved therapy for inducible urticaria. Many patients remain symptomatic even on treatment. Omalizumab shows effectiveness for some people with antihistamine-resistant inducible urticaria, though it’s used off-label for this purpose.24PubMed. Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria Newer agents like BTK inhibitors and anti-KIT antibodies are also being studied for these subtypes.
For cold urticaria specifically, avoidance strategies are genuinely important. Swimming in cold water can cause massive histamine release and, in extreme cases, anaphylaxis. People with diagnosed cold urticaria should carry an epinephrine auto-injector and avoid sudden full-body cold exposure.
Biomarkers and the Shift Toward Personalized Treatment
One of the more exciting developments in hives research is the push to identify biomarkers that predict which patients will respond to which treatments. Chronic spontaneous urticaria is increasingly recognized as having distinct subtypes: a Type I endotype driven by IgE-mediated autoimmunity and a Type IIb endotype driven by IgG autoantibodies. Markers like total IgE levels, C-reactive protein, and basophil counts are showing promise in predicting disease severity and likely response to specific therapies.25Current Treatment Options in Allergy. Biomarkers in Chronic Spontaneous Urticaria: Are We Ready for its Use in Clinical Practice? In practice, this means that the era of trial-and-error treatment selection may eventually give way to blood-test-guided decision-making, where your biomarker profile helps predict whether omalizumab, dupilumab, or remibrutinib is the best fit.
When Hives Aren’t Really Hives
If your welts each last longer than 24 hours in the same spot, leave behind a bruise or brownish discoloration when they fade, or come with joint pain, fever, or belly pain, the diagnosis may not be ordinary urticaria at all. Urticarial vasculitis is a condition that looks like hives on the surface but involves inflammation of small blood vessels underneath. Experts recommend a skin biopsy when wheals persist beyond 24 hours or leave residual color changes, because the treatment approach for vasculitis differs from standard urticaria management.26PubMed Central. Differential diagnosis between urticarial vasculitis and chronic spontaneous urticaria: An international Delphi survey If antihistamines and even biologics aren’t touching your symptoms and your welts behave this way, asking about urticarial vasculitis is worth doing rather than simply escalating hives treatments that were never designed for a different underlying problem.